0RAG.LSE ABIONYX Pharma S.A.
- Market cap
- EUR 78.3M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0RAG.LSE undervalued?
Graham numberThe Graham number of ABIONYX Pharma S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ABIONYX Pharma S.A. fundamental analysis
No fundamental analysis for ABIONYX Pharma S.A. yet.
ABIONYX Pharma S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ABIONYX Pharma S.A.
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase …
Full company profileABIONYX Pharma S.A. financial statements
ABIONYX Pharma S.A. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | - | - | 174K | - | - | - |
| Operating Income | -24.0M | -6.64M | -7.05M | -2.53M | -2.97M | - |
| Net Income | -24.9M | -4.98M | -6.31M | 1.85M | -1.89M | - |
| Balance Sheet | ||||||
| Total Assets | 29.1M | - | 13.1M | 10.2M | 10.3M | - |
| Total Liabilities | 14.5M | - | 9.30M | 3.58M | 3.66M | - |
| Shareholders' Equity | 14.6M | - | 3.84M | 6.67M | 6.63M | - |
| Cash & Short-term Investments | 24.7M | - | 11.5M | 8.33M | 9.15M | - |
| Total Debt | 6.76M | - | 500K | 23.0K | - | - |
| Cash Flow | ||||||
| Operating Cash Flow | -19.2M | -9.09M | -6.00M | -3.95M | -599K | -6.70M |
| Capital Expenditure | 5.00K | 23.0K | 23.0K | 103K | 103K | 0.00 |
| Ratios | ||||||
| ROE | -170.2% | - | -164.3% | 27.7% | -28.5% | - |
| ROA | -85.6% | - | -48.0% | 18.0% | -18.3% | - |
| Net Profit Margin | - | - | -3,624.1% | - | - | - |
| Debt to Equity | 0.46x | - | 0.13x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ABIONYX Pharma S.A. dividends
ABIONYX Pharma S.A. has not paid dividends in the last 9 fiscal years.
Last stock split: 66:65 on May 29, 2026.
Who owns ABIONYX Pharma S.A.
- Insiders 28.95%
- Institutions 3.61%
- Public & others 67.44%
- Shares outstanding 18.2M
- Free float 22.7M
ABIONYX Pharma S.A. company profile
- Company name
- ABIONYX Pharma S.A.
- Ticker
- 0RAG.LSE
- ISIN
- FR0012616852
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 49
- Fiscal year end
- December
- Address
- Building D2, Balma, France, 31130
- Phone
- 33 5 62 24 97 06
- Website
- abionyx.com
About ABIONYX Pharma S.A.
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency, as well as in a Phase II trial for the treatment of sepsis. It is also developing ABNX-100, a strategic extension into ophthalmology of CER-001 that is in preclinical trial for the treatment of uveitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was incorporated in 2005 and is headquartered in Balma, France.
ABIONYX Pharma S.A. management
5- Sir Cyrille Tupin CPACEO, GM & Director · born 1977
- Prof. Christian Chavy MBAIndependent Director · born 1950
- Mr. Emmanuel De FougerouxAdministrative & Financial Director
- Ms. Constance Keyserling Peyrottes M.S.Vice President of Clinical, Regulatory Development & Operations · born 1961
- Mr. Laurent GuerciChief Digital & Innovation Officer